Infectious diseases specialists diagnose and treat infections from bacteria, viruses, fungi, and parasites, focusing on fevers, antibiotics, and vaccines.
Send us all your questions or requests, and our expert team will assist you.
Diagnosing Hepatitis C involves a sequential two-step process that distinguishes between past exposure and current active infection. Because the disease is asymptomatic, diagnosis is often incidental, occurring during routine blood screening, insurance exams, or blood donation. The first step in the algorithm is the HCV Antibody Test (anti-HCV). This serological test detects antibodies produced by the immune system in response to the virus.
A non-reactive (negative) antibody test generally indicates that the person has never been infected. However, a reactive (positive) antibody test does not confirm active disease; it simply shows that the person has been exposed to the virus at some point in their life. Because approximately 20% to 30% of people spontaneously clear the infection without treatment, they retain antibodies for life even if they no longer have the virus. Therefore, a positive antibody test must always be followed by a confirmatory test: the HCV RNA PCR (Polymerase Chain Reaction).
The HCV RNA test detects the virus’s genetic material in the blood. A positive RNA test confirms active, chronic infection and necessitates medical evaluation. If the antibody is positive but the RNA is negative, the patient has cleared the infection (either naturally or through past treatment) and requires no further intervention for the virus itself. This distinction is crucial to prevent unnecessary anxiety and treatment.
Once active infection is confirmed by HCV RNA testing, further molecular evaluation is performed to characterize the virus. Historically, determining the viral genotype (1 through 6) was the most critical step in planning treatment, as older interferon-based therapies had vastly different success rates depending on the strain. While modern “pan-genotypic” drugs are effective across most strains, genotyping remains a standard part of the evaluation in many protocols to optimize treatment duration and detect potential drug resistance, particularly in patients with cirrhosis or prior treatment failure.
Quantitative RNA testing, often called the “viral load,” measures the amount of virus in the blood (in International Units per milliliter). Unlike in HIV, the viral load in Hepatitis C does not necessarily correlate with the severity of liver damage; a patient can have a very high viral load with minimal scarring, or a low load with advanced cirrhosis. However, viral load serves as a baseline for monitoring adherence and response to therapy. A “Sustained Virologic Response” (SVR), defined as an undetectable viral load 12 weeks after completing treatment, is the clinical definition of a cure.
Evaluating the stage of liver fibrosis is the single most important prognostic step. It determines the urgency of treatment, the duration of therapy, and the need for long-term surveillance for liver cancer. Historically, the liver biopsy—inserting a needle into the liver to extract tissue—was the gold standard. However, due to its invasive nature and risk of bleeding, it has largely been replaced by non-invasive technologies in routine practice.
Transient Elastography (often known by the trade name FibroScan) is the most common non-invasive tool. It uses ultrasound-based technology to send a shear wave through the liver. The wave speed correlates with liver tissue stiffness; a stiffer liver indicates greater fibrosis. This test provides a score (in kilopascals) that corresponds to the Metavir scale (F0-F4). Other methods include Shear Wave Elastography and Magnetic Resonance Elastography (MRE), which offer high precision.
For settings where imaging is unavailable, serological fibrosis markers are used. Algorithms such as the FIB-4 index and APRI score calculate a fibrosis risk score using standard blood test values (age, AST, ALT, and platelet count). These calculators are highly effective at ruling in or ruling out advanced cirrhosis, helping clinicians triage patients for specialized care.
A comprehensive evaluation extends beyond the liver to assess the virus’s systemic impact. A Complete Blood Count (CBC) is essential; a low platelet count (thrombocytopenia) is a surrogate marker for portal hypertension and advanced cirrhosis. Liver function tests (ALT, AST, Bilirubin, Albumin, INR) assess the liver’s synthetic capacity and the degree of ongoing inflammation.
Given the strong association with metabolic and renal disease, the workup includes screening for diabetes (HbA1c), renal function (creatinine, eGFR), and a lipid profile. Screening for coinfections is mandatory; all patients diagnosed with HCV must be tested for HIV and Hepatitis B (HBV). Co-infection alters the natural history of the disease and requires careful management to prevent HBV reactivation during Hepatitis C treatment.
For patients identified as having advanced fibrosis (F3) or cirrhosis (F4), the evaluation includes immediate screening for liver cancer. This typically involves a liver ultrasound and the measurement of Alpha-fetoprotein (AFP), a tumor marker. Even after the virus is cured, patients with established cirrhosis remain at risk for HCC and require lifelong surveillance every six months. The initial evaluation sets the cadence for this long-term monitoring plan.
Patients reporting symptoms suggestive of extrahepatic involvement require targeted evaluation. Urinalysis is used to detect protein or blood, indicating kidney involvement (glomerulonephritis). Rheumatoid factor and cryoglobulin levels are checked if vasculitis is suspected. This holistic approach ensures that the systemic burden of the disease is documented and addressed alongside the viral eradication.
Send us all your questions or requests, and our expert team will assist you.
Not necessarily. A positive antibody test only means you have been exposed to the virus at some point in your life. Your body produces antibodies to fight the infection. About 25% of people clear the virus naturally but keep the antibodies forever. You need a second test, called an RNA test, to determine whether the virus is currently present in your blood.
In most modern clinical settings, a liver biopsy is no longer required. Doctors now use non-invasive tests such as Transient Elastography (FibroScan) or blood test formulas (such as FIB-4) to measure liver scarring and stiffness. These are painless, quick, and provide the necessary information to plan treatment.
The viral load is a measurement of the amount of Hepatitis C genetic material (RNA) in a specific amount of your blood. It confirms active infection. While a high viral load means you are contagious via blood contact, it does not tell you how damaged your liver is. The goal of treatment is to reduce this viral load to zero.
Because Hepatitis C, Hepatitis B, and HIV share similar routes of transmission (blood-to-blood contact), co-infection is possible. Treating Hepatitis C can sometimes reactivate a dormant Hepatitis B infection, and HIV complicates the immune response. Knowing your status for all three ensures the doctor chooses a safe and effective treatment plan.
Transient Elastography (FibroScan) is highly accurate for detecting severe scarring (cirrhosis) or the absence of scarring. It is slightly less precise for the middle stages of fibrosis. However, when combined with blood tests and clinical history, it provides a reliable picture of liver health for the vast majority of patients without the risks of a needle biopsy.
Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.
Your Comparison List (you must select at least 2 packages)
